Andrew Calinisan

1 ta ish

Mirati Therapeutics (United States)

1. The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients

   Jill Hallin, Lars D. Engstrom, Lauren Hargis +31

   MaqolaOAOchiq kirish20192 iqtibos

   ABIABI:AkademIndex/2026.other.241952